The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03B | Other drugs for obstructive airway diseases, inhalants | |
| 4 | R03BC | Antiallergic agents, excl. corticosteroids | |
| 5 | R03BC01 | Cromoglicic acid |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| RESPIR - Respiratory (Inhalation) (aerosol) | 40 mg |
| RESPIR - Respiratory (Inhalation) (powder) | 80 mg |
| RESPIR - Respiratory (Inhalation) (solution) | 80 mg |
| Active Ingredient | Description | |
|---|---|---|
| Cromoglicic acid |
Sodium cromoglicate (Cromoglicic acid) inhibits the activation of many of the cell types involved in the development and progression of asthma. Thus, sodium cromoglicate inhibits the release of inflammatory mediators including cytokines from mast cells and reduces the chemotactic activity of eosinophils and neutrophils. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| INTAL CFC-FREE Pressurised inhalation, suspension | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| NALCROM Capsule | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
